Log in

2162 Keymed Biosciences, Inc. HKEX · China

Keymed Biosciences (2162) news

Keymed Biosciences, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2162, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Keymed Biosciences news

We have not published a story on Keymed Biosciences yet. When there is news, it will appear here.

Questions about Keymed Biosciences

What is the ticker symbol of Keymed Biosciences?

Keymed Biosciences, Inc. trades under the ticker 2162 on HKEX.

Where is Keymed Biosciences listed?

Keymed Biosciences, Inc. is listed on HKEX. Our directory also records these other listings: LSX:A3CTJD.

Which country or territory is Keymed Biosciences listed under?

Our directory records Keymed Biosciences, Inc. under China.

What does Keymed Biosciences do?

Our directory classifies Keymed Biosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Keymed Biosciences?

The ISIN recorded for Keymed Biosciences, Inc. is KYG5252B1023.

Does aibio.space cover Keymed Biosciences?

aibio.space lists Keymed Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Keymed Biosciences?

Companies in our directory listed in the same country and business area as Keymed Biosciences: Shandong Wohua Pharmaceutical Co., China Resources Boya Bio-pharmaceutical Group Co., Pharmaron Beijing Co., Zhejiang Shengda Bio-Pharm Co., China National Medicines Corporation, Guhan Pharmaceutical Group Co..

Investor discussion: Keymed Biosciences

Members talk about Keymed Biosciences (2162). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Keymed Biosciences, newest first. Each line links the filing it comes from.

  1. Mergers

    Transaction under the Listing Rules: SUPPLEMENTAL ANNOUNCEMENT TO DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES. Source

  2. Mergers

    Transaction under the Listing Rules: DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES. Source

  3. Financings

    Share or debt issue: COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE. Source

  4. Financings

    Share or debt issue: (1) PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE AND (2) SALE OF SHARES BY THE TOP-UP VENDOR. Source

Press releases

Headlines of Keymed Biosciences's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    INSIDE INFORMATION ANNOUNCEMENT-(1) UPDATE ON PRODUCT REVENUE FOR THE FIRST THREE QUARTERS OF 2026 AND (2) NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES THE NEW INDICATION MARKETING APPLICATION FOR STAPOKIBART FOR THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN ADOLESCENTS

  2. HKEXnews

    RESIGNATION OF NON-EXECUTIVE DIRECTOR

  3. HKEXnews

    VOLUNTARY ANNOUNCEMENT - ENTERED INTO A LICENSING AGREEMENT IN RELATION TO THE MARKETING REGISTRATION AND COMMERCIALIZATION OF STAPOKIBART INJECTION IN 18 COUNTRIES AND REGIONS INCLUDING SOUTHEAST ASIA AND CENTRAL ASIA

  4. HKEXnews

    INSIDE INFORMATION - PROPOSED ISSUE OF RMB SHARES AND LISTING ON THE SCI-TECH BOARD OF THE SHANGHAI STOCK EXCHANGE

  5. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2026

  6. HKEXnews

    INSIDE INFORMATION ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF CM512 (TSLP x IL-13 BISPECIFIC ANTIBODY) INJECTION FOR PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS ACHIEVED ALL STUDY ENDPOINTS

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT - CMG901 (AZD0901) CLARITY-Gastric01 GLOBAL PHASE III CLINICAL TRIAL ACHIEVES POSITIVE TOPLINE RESULTS

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT - CM512 INCLUDED IN THE BREAKTHROUGH THERAPY DESIGNATION LIST BY THE CENTER FOR DRUG EVALUATION OF THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

  9. HKEXnews

    INSIDE INFORMATION ANNOUNCEMENT - (1) UPDATE ON PRODUCT REVENUE FOR THE FIRST HALF OF 2026 AND (2) POSITIVE PROFIT ALERT

  10. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026

  11. HKEXnews

    VOLUNTARY ANNOUNCEMENT - UPDATE ON DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES

  12. HKEXnews

    NOTICE OF ANNUAL GENERAL MEETING

  13. HKEXnews

    SUPPLEMENTAL ANNOUNCEMENT TO DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES

  14. HKEXnews

    ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025

  15. HKEXnews

    DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES

  16. HKEXnews

    VOLUNTARY ANNOUNCEMENT - UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 (AZD0901)

  17. HKEXnews

    INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025; AND RESIGNATION OF CHIEF FINANCIAL OFFICER AND JOINT COMPANY SECRETARY

  18. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2025

  19. HKEXnews

    COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE

  20. HKEXnews

    (1) PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER THE GENERAL MANDATE AND (2) SALE OF SHARES BY THE TOP-UP VENDOR

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2162 on TradingView.

Listing details

Keymed Biosciences, Inc. is a public biotech or pharmaceutical company listed on HKEX under the ticker 2162, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Keymed Biosciences, Inc.
Ticker
2162
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
KYG5252B1023
Other listed symbols
LSX:A3CTJD
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.